Showing results (101-110 of 310) with videos related to

Sort By:
Pageof 31
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosisPolyzois Makras, Stergios A Polyzos, Athanasios D Anastasilakis, et al.
Frontiers in Endocrinology|March 16, 2026
Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic miceVagelis Rinotas, Eleftheria-Dimitra Ntouskou, Melina Dragolia, et al.
Medicina (Kaunas, Lithuania)|October 23, 2021
Inherited/Genetically-Associated Pheochromocytoma/ Paraganglioma Syndromes and COVID-19Ioannis Ilias, Gregory Kaltsas, Konstantinos Barkas, et al.
Hormones (Athens, Greece)|January 7, 2016
Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?Iraklis Perysinakis, Chrysanthi Aggeli, Gregory Kaltsas, et al.
Expert Opinion on Therapeutic Targets|November 15, 2014
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatmentAthanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, et al.
Metabolism: Clinical and Experimental|July 23, 2015
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markersAthanasios D Anastasilakis, Stergios A Polyzos, Zoe A Efstathiadou, et al.
Archives of Osteoporosis|October 17, 2018
Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek populationEffimia V Grigoriou, George Trovas, Nikolaos Papaioannou, et al.
Pageof 31